Drug Trial Radar · NCT05171673
Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
151
Actual
Start
Oct 31, 2021
Primary completion
Jun 30, 2024
Study completion Jul 12, 2024
Sponsor
- Lead sponsor
- IBSA Institut Biochimique SAIndustry
- Sponsor type
- Industry
- First posted
- Dec 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multi-center, prospective, open-label, controlled study of the pharmacokinetics and safety of the LicartTM topical system in pediatric and adult participants with minor soft tissue injuries. 150 male and female participants aged 6-16 and 18-45 with soft tissue injuries meeting the following criteria will be enrolled to evaluate the pharmacokinetics and safety of the Licart topical system in pediatric and adult participants with minor soft tissue injuries over a 14-day treatment course. The analgesic effects will also be evaluated of the topical system in pediatric and adult participants with minor soft tissue injuries over a 14-day treatment course. To collect principal investigator-reported global response to therapy.
Conditions
- Soft Tissue Injuries
Interventions
Licart™ (diclofenac epolamine) topical systemDrug
The Licart™ (diclofenac epolamine) topical system was designed to deliver the nonsteroidal anti-inflammatory drug (NSAID) diclofenac to the site of a minor soft tissue injury through topical application. This investigational product (IP) is a 10 cm x 14 cm topical system comprised of an adhesive material containing 1.3% diclofenac epolamine that is bound to a non-woven polyester felt backing and covered with a polypropylene film release liner. The release liner is removed prior to topical application to the skin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma Diclofenac Concentration of Licart™ Topical System at V2 and V5/EOS.Time frame: 24 hours post-application (day 2 - V2), and Day 14 (V5) or one day after pain resolution (EOS)
- Local Tolerability of the Licart™ Topical System as Assessed by a 7-point Scale.Time frame: 24 hours post-application (day 2 - V2), Day 4 (V3), Day 7 (V4), and Day 14 (V5) or EOS (the day after pain resolution)
- Number of Participants With Adverse Events as Assessed by the Study TeamTime frame: 14 days after participant received first dose
- Pharmacokinetics of the Licart™ Topical System as Assessed by the Activated Partial Thromboplastin Time (aPTT)Time frame: 24 hours post-application (day 2 - V2), and Day 14 (V5) or one day after pain resolution (EOS)
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Applied Research Center
Little Rock, Arkansas
Atella Clinical Research, LLC.
La Palma, California
University Clinical Research - Deland, LLC
DeLand, Florida
My Community Research, Inc.
Miami, Florida
D & H Tamarac Research Centers, Inc.
Tamarac, Florida
Research Integrity
Owensboro, Kentucky
Ascendant Research Clinic, LLC.
Alamogordo, New Mexico
Prime Global Research Inc.
The Bronx, New York
Ascendant Research Clinic, LLC.
Marion, South Carolina
Next Level Urgent Care
Houston, Texas
AIM Trials
Plano, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.